Patents by Inventor John R. Desjarlais

John R. Desjarlais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20180215822
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: February 9, 2018
    Publication date: August 2, 2018
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20180162950
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: September 20, 2017
    Publication date: June 14, 2018
    Inventors: Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
  • OPTIMIZED ANTIBODIES THAT TARGET CD19
    Publication number: 20180148511
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: September 22, 2017
    Publication date: May 31, 2018
    Applicant: XENCOR, INC.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • OPTIMIZED FC VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20180141997
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: June 26, 2017
    Publication date: May 24, 2018
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 9914778
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: March 13, 2018
    Assignee: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Methods and compositions for inhibiting CD32b expressing cells
    Patent number: 9902773
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: February 27, 2018
    Assignee: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • OPTIMIZED ANTIBODIES THAT TARGET CD19
    Publication number: 20180009900
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 11, 2018
    Applicant: XENCOR, INC.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20170335013
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: March 16, 2017
    Publication date: November 23, 2017
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Optimized antibodies that target CD19
    Patent number: 9803020
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: October 31, 2017
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Fc variants with altered binding to FcRn
    Patent number: 9803023
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: October 31, 2017
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
  • Optimized Fc variants and methods for their generation
    Patent number: 9714282
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: July 25, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Heterodimeric proteins
    Patent number: 9701759
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: July 11, 2017
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9617348
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: April 11, 2017
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Optimized anti-CD30 antibodies
    Patent number: 9574006
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: February 21, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-lu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9540451
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: January 10, 2017
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 9394366
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: July 19, 2016
    Assignee: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20160176982
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: November 2, 2015
    Publication date: June 23, 2016
    Inventors: Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20160122435
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: January 11, 2016
    Publication date: May 5, 2016
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Methods and compositions for inhibiting CD32b expressing cells
    Patent number: 9260523
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: February 16, 2016
    Assignee: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Fc variants with altered binding to FcRn
    Patent number: 9200079
    Abstract: The present application relates to optimized IgG immunoglobulin engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: December 1, 2015
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean Christopher Yoder